Merbarone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206756

CAS#: 97534-21-9

Description: Merbarone, also known as NSC-336628; RLBN-1001, is a Type II DNA topoisomerase inhibitor potentially for the treatment of solid tumors. Merbarone induces activation of caspase-activated DNase and excision of chromosomal DNA loops from the nuclear matrix. Merbarone induces apoptosis in CEM cells through activation of ICE/CED-3-like protease. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.

Chemical Structure

img
Merbarone
CAS# 97534-21-9
Instruction

Theoretical Analysis

MedKoo Cat#: 206756
Name: Merbarone
CAS#: 97534-21-9
Chemical Formula: C11H9N3O3S
Exact Mass: 263.04
Molecular Weight: 263.271
Elemental Analysis: C, 50.18; H, 3.45; N, 15.96; O, 18.23; S, 12.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Merbarone; NSC-336628; RLBN-1001; NSC336628; RLBN1001.

IUPAC/Chemical Name: 5-(N-Phenylcarboxamido)-2-thiobarbituric acid

InChi Key: KIHGHKYNPNVMLM-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H9N3O3S/c15-6-14(7-4-2-1-3-5-7)8-9(16)12-11(18)13-10(8)17/h1-6,8H,(H2,12,13,16,17,18)

SMILES Code: S=C(NC(C1N(C2=CC=CC=C2)C=O)=O)NC1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 263.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Spallarossa A, Rotolo C, Sissi C, Marson G, Greco ML, Ranise A, La Colla P, Busonera B, Loddo R. Further SAR studies on bicyclic basic merbarone analogues as potent antiproliferative agents. Bioorg Med Chem. 2013 Nov 1;21(21):6328-36. doi: 10.1016/j.bmc.2013.08.056. PubMed PMID: 24063907.

2: Pastor N, Domínguez I, Orta ML, Campanella C, Mateos S, Cortés F. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res. 2012 Oct-Nov;738-739:45-51. doi: 10.1016/j.mrfmmm.2012.07.005. PubMed PMID: 22921906.

3: Attia SM. Dominant lethal mutations of topoisomerase II inhibitors etoposide and merbarone in male mice: a mechanistic study. Arch Toxicol. 2012 May;86(5):725-31. doi: 10.1007/s00204-011-0799-6. PubMed PMID: 22207148.

4: Wang L, Roy SK, Eastmond DA. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells. Mutat Res. 2007 Mar 1;616(1-2):70-82. PubMed PMID: 17174356.

5: Otake Y, Mims A, Fernandes DJ. Merbarone induces activation of caspase-activated DNase and excision of chromosomal DNA loops from the nuclear matrix. Mol Pharmacol. 2006 Apr;69(4):1477-85. PubMed PMID: 16434617.

6: Ranise A, Spallarossa A, Schenone S, Bruno O, Bondavalli F, Pani A, Marongiu ME, Mascia V, La Colla P, Loddo R. Synthesis and antiproliferative activity of basic thioanalogues of merbarone. Bioorg Med Chem. 2003 Jun 12;11(12):2575-89. PubMed PMID: 12757725.

7: Snyder RD. Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisons. Drug Chem Toxicol. 2003 Feb;26(1):15-22. PubMed PMID: 12643037.

8: Attia SM, Kliesch U, Schriever-Schwemmer G, Badary OA, Hamada FM, Adler ID. Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe. Environ Mol Mutagen. 2003;41(2):99-103. PubMed PMID: 12605378.

9: Wang L, Eastmond DA. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187. Environ Mol Mutagen. 2002;39(4):348-56. PubMed PMID: 12112387.

10: Khélifa T, Beck WT. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease. Mol Pharmacol. 1999 Mar;55(3):548-56. PubMed PMID: 10051540.

11: Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. J Biol Chem. 1998 Jul 10;273(28):17643-50. PubMed PMID: 9651360.

12: Malik UR, Dutcher JP, Caliendo G, Lasala P, Mitnick R, Wiernik PH. Phase II trial of merbarone in patients with malignant brain tumors. Med Oncol. 1997 Sep-Dec;14(3-4):159-62. PubMed PMID: 9468039.

13: Mo YY, Wang Q, Beck WT. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3. Cancer Res. 1997 Nov 15;57(22):5004-8. PubMed PMID: 9371492.

14: Kallio M, Lähdetie J. Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: cell cycle arrest and induction of aneuploidy. Environ Mol Mutagen. 1997;29(1):16-27. PubMed PMID: 9020303.

15: Kusumoto H, Rodgers QE, Boege F, Raimondi SC, Beck WT. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res. 1996 Jun 1;56(11):2573-83. PubMed PMID: 8653700.

16: Look KY, Blessing JA, Adelson MD, Morris M, Bookman MA. A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol. 1996 Feb;19(1):7-9. PubMed PMID: 8554040.

17: Look KY, Blessing JA, Williams L, Morris M. A phase II trial of merbarone (NSC 336628) as salvage therapy for squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol. 1995 Oct;18(5):441-3. PubMed PMID: 7572765.

18: Chen M, Beck WT. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res. 1995 Apr 1;55(7):1509-16. PubMed PMID: 7882360.

19: Slavik M, Liu PY, Kraut EH, Natale RB, Flaherty LE, Sondak VK. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study. Invest New Drugs. 1995;13(2):143-7. PubMed PMID: 8617577.

20: Ajani JA, Winn R, Baez L, Pollock T, Maher T, Hallinan-Fueger B, Newman J. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. Cancer Invest. 1994;12(5):488-90. PubMed PMID: 7922705.